Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

研究还发现，CAR-T细胞疗法后T细胞恶性肿瘤的累积发生率在治疗后1年、2年和3年均为0%，在4年时为0.6%（95%置信区间为0.1%-3.1%），如fig1所示。这一数据表明，随着时间推移，T ...

Incyte (NASDAQ:INCY – Free Report) had its price objective hoisted by Stifel Nicolaus from $75.00 to $77.00 in a report released on Monday morning,Benzinga reports. Stifel Nicolaus currently has a ...

Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today reported its financial results for ...

A bright, colorful banner made of stapled-together pennants waves at the top of a small hill in the Myer family’s front yard ...